Injectable fillers are the other half of injection treatments (Botox is the other half) that have revolutioned the approach to facial. Evolving from the first FDA-approved injectable filler in 2002 (Restylane), there are now over a dozen different facial fillers from various manufacturers. The latest filler options have become focused on filling a specific type of facial volume indication which is not a surprise as the filler field has become crowded and new product introductions must fill a specific niche to become a used option.
Such is the role that the latest facial filler that has just received FDA approval has. Juvederm Voluma XC (Allergan) is the first and only filler approved to treat age-related volume loss in the cheek. (midface) It has been shown in clinical trials to create a more youthful appearance in the face with results that can last up to two years. The value of this long-lasting but temporary filler treatment is that as people age the cheeks lose volume and sag, creating a midfacial flattening look. Adding back volume with Voluma XC helps restore convexity back to the cheek area, like a poor man’s submalar cheek implant.
Juvederm Voluma XC is made with the proprietary Vycross technology that allows the gel to be injected smoothly and consistently through a needle or microcannula. Like other Juvederm products, it also contains lidocaine which provides a numbing effect during the treatment. Juvederm Voluma XC is not new, it has been used in Europe since 2005 without lidocaine and since 2009 with lidocaine in it. The potential side effects with its use are exactly like that of any filler, temporary swelling, bruising, and lumps and irregularities.
Juvderm Voluma XC is a hyaluronic-acid injectable filler that can now rival other fillers used for their facial volumizing effects such as Sculptra and Radiesse.
Dr. Barry Eppley
Indianapolis, Indiana